Latest / The Well-Built Life / The Hidden Risks of Statin Therapy
Transcript
- 0:00Speaker 1: Hey everyone, welcome back to The Well-Built Life. I am
- 0:03Speaker 1: Rachel Caldwell, alongside Thomas Bennett, and we are so glad
- 0:07Speaker 1: you are tuning in. We are here to cut through
- 0:09Speaker 1: the noise, skip the intense jargon and extreme rules, and
- 0:13Speaker 1: share simple practical habits that help you feel stronger, healthier,
- 0:17Speaker 1: and more balanced every single day. Grab a drink, get comfortable,
- 0:21Speaker 1: and let's dive in. Welcome, Thomas, to our show, The
- 0:25Speaker 1: Well-Built Life. Today, we are exploring a fascinating topic, The
- 0:30Speaker 1: journey of statins not just medically, but also the less
- 0:34Speaker 1: talked about consequence of their use. Coenzyme Q10 deficiency. Statins
- 0:39Speaker 1: are prescribed all the time for high cholesterol. But have
- 0:43Speaker 1: you ever stopped to consider what else might be happening
- 0:46Speaker 1: in our bodies?
- 0:47Speaker 2: Hi, Rachel. I have to say, I have been looking
- 0:50Speaker 2: forward to this. When we prescribe something so regularly, Therese
- 0:55Speaker 2: always more to it than meets the eye. Statins reduce
- 0:58Speaker 2: cholesterol by inhibiting cholesterol production in the liver. But what
- 1:02Speaker 2: happens when you cut off a fundamental process your body
- 1:05Speaker 2: relies on?
- 1:05Speaker 1: That's exactly right, Thomas. The assumption is straightforward and seemingly
- 1:10Speaker 1: so effective. Lower cholesterol, reduce heart risk. But what we
- 1:14Speaker 1: have been missing is that 75% of our cholesterol is
- 1:18Speaker 1: made in the body for essential functions. It's not just
- 1:21Speaker 1: about the numbers, but the intricate balance the body needs.
- 1:24Speaker 2: Exactly. Like playing with a Rubik's Cube where every piece
- 1:27Speaker 2: is connected, statins block EMG-CoA reductase, inhibiting cholesterol synthesis, but
- 1:33Speaker 2: they also interfere with Q10 production. This is a crucial
- 1:37Speaker 2: point because, as you mentioned, Q10 is vital for energy
- 1:41Speaker 2: production in the heart and muscles.
- 1:43Speaker 1: Right, and that's the crucial nuance here. The pharmaceutical giant
- 1:48Speaker 1: Merck had a patent in mind that could have ensured
- 1:50Speaker 1: Q10 coexisted with statins, but it was never fully utilized.
- 1:56Speaker 1: What does that say about the industry's true intentions?
- 1:59Speaker 2: It's a red flag, Rachel. The patent could have been
- 2:02Speaker 2: a game changer, ensuring that the body's natural processes weren't
- 2:06Speaker 2: completely disrupted. Yet, the lack of implementation raises questions. Could
- 2:11Speaker 2: it be that profits override scientific integrity when it comes
- 2:15Speaker 2: to drug patents?
- 2:16Speaker 1: Exactly. Which brings up an interesting contradiction. The American Heart
- 2:20Speaker 1: Association and American College of Cardiology have issued guidelines that
- 2:24Speaker 1: that largely focus on statin prescriptions. But what about SUSU10,
- 2:29Speaker 1: despite research showing its benefits, to raise little emphasis given
- 2:33Speaker 1: to supplementation?
- 2:34Speaker 2: And this, my dear Rachel, is like prescribing a medicine
- 2:38Speaker 2: while forgetting to tell half the story. Doctors often don't
- 2:42Speaker 2: bring up CO10, aligning with the status quo. Patients, on
- 2:46Speaker 2: the other hand, are usually unaware of the potential side
- 2:50Speaker 2: effects and the need for CO10.
- 2:52Speaker 1: So, let's dive into the numbers. According to the dossier,
- 2:56Speaker 1: 93 million people in the U.S. are prescribed statins. But
- 3:00Speaker 1: when we delve deeper, Tariya has evidence from 12 human
- 3:03Speaker 1: randomized controlled trials that showed significant benefits of CO10 in
- 3:08Speaker 1: preventing statin side effects.
- 3:09Speaker 2: That's a staggering number, and let's not forget the risk
- 3:13Speaker 2: of tendon rupture. 500 mg of ubiquinol is recommended to
- 3:17Speaker 2: mitigate this risk. It's clear that even in their current form,
- 3:21Speaker 2: Statins are just part of a bigger, complex ecosystem affecting
- 3:25Speaker 2: our health. True.
- 3:27Speaker 1: And this ecosystem is far from static. The dossier critiques
- 3:32Speaker 1: the industry's assumptions and the lack of transparency in informed consent.
- 3:38Speaker 1: Questions of conflict of interest with health organizations recommending the
- 3:43Speaker 1: status quo persist. Is there a move towards a more
- 3:46Speaker 1: evidence-based approach? that prioritizes the root causes of high cholesterol?
- 3:52Speaker 2: Indeed, there might be. Teresa's significant push for public awareness
- 3:57Speaker 2: and education about these drugs and their consequences. This is
- 4:01Speaker 2: about more than just treating symptoms. It's about empowering patients
- 4:04Speaker 2: with the knowledge they need to make informed decisions about
- 4:07Speaker 2: their health.
- 4:08Speaker 1: And that's where our episode comes in. We are going
- 4:11Speaker 1: to delve into these layers and help our listeners understand
- 4:14Speaker 1: the full picture. Stay with us. Let's break down how
- 4:17Speaker 1: statins work in the body and why Q10 is a
- 4:20Speaker 1: critical factor. You remember that statins inhibit the enzyme HEMG-QA reductase,
- 4:27Speaker 1: reducing cholesterol synthesis. But what else do we need to
- 4:31Speaker 1: consider here?
- 4:31Speaker 2: Exactly. When statins block this enzyme, they also block the
- 4:35Speaker 2: production of Q10, which is essential for energy production in cells,
- 4:40Speaker 2: especially in the heart and muscles. It's a double-edged sword. So,
- 4:46Speaker 2: how do we quantify the impact of this depletion? Indeed,
- 4:49Speaker 2: and the risk of tendon rupture, which is a common
- 4:52Speaker 2: side effect of statins, can be mitigated with just 500
- 4:55Speaker 2: mg of ubiquinol daily. This is a practical action item
- 5:00Speaker 2: that patients can take to protect themselves.
- 5:02Speaker 1: And when we look at the stakeholders, the pharmaceutical companies
- 5:05Speaker 1: like Merck, who held the patent to coexist with COX-10,
- 5:09Speaker 1: didn't implement it. Why? Is it purely a financial decision?
- 5:14Speaker 1: Or are there deeper issues?
- 5:16Speaker 2: It's hard to say, but there are certainly questions. The
- 5:20Speaker 2: AHA and ATC have been criticized for their lack of
- 5:23Speaker 2: emphasis on CoQ10. If you look at their guidelines, they
- 5:27Speaker 2: fail to mention it, which could indicate a conflict of interest,
- 5:31Speaker 2: but let's not jump to conclusions. We need more data.
- 5:35Speaker 1: That's true. What about doctors? Are they aware of the
- 5:39Speaker 1: role of CoQ10 and its importance? Do they promote it?
- 5:44Speaker 1: Or do they just stick to the statins because that's
- 5:47Speaker 1: the status quo?
- 5:48Speaker 2: Often, doctors aren't well-versed in the nuances. They focus on
- 5:52Speaker 2: the effectiveness of statins, which is easy to measure in
- 5:55Speaker 2: terms of lowering cholesterol. But when it comes to the
- 5:58Speaker 2: prevention of side effects, they might hesitate to prescribe something
- 6:02Speaker 2: that isn't as easily measurable.
- 6:04Speaker 1: Exactly. And what about patients? Do they know that lowering
- 6:08Speaker 1: cholesterol isn't the whole story? And they might need Coke
- 6:12Speaker 1: 10 to maintain their health?
- 6:13Speaker 2: Typically, no. Many patients just take their statins and think
- 6:17Speaker 2: they are doing enough. But as we have seen, the
- 6:20Speaker 2: body needs CO10 for energy production, and ignoring it can
- 6:24Speaker 2: lead to serious consequences. That's why informed consent is so important.
- 6:29Speaker 1: Absolutely. It's a stark reminder of the complexity in healthcare.
- 6:33Speaker 1: We need to advocate for more comprehensive solutions that address
- 6:37Speaker 1: the root causes of high cholesterol. That might mean focusing
- 6:41Speaker 1: on diet and lifestyle changes. rather than just relying on statins.
- 6:45Speaker 2: And to raise the rub, the data suggests that a
- 6:48Speaker 2: shift towards a more evidence-based approach could lead to better outcomes.
- 6:52Speaker 2: Maybe moving away from the blanket prescription of statins and
- 6:56Speaker 2: towards more tailored treatments that include factors like Q10 supplementation
- 6:59Speaker 2: could be the way forward.
- 7:00Speaker 1: That's a compelling perspective. As we continue to explore these issues,
- 7:05Speaker 1: we hope to empower our listeners to make informed decisions
- 7:08Speaker 1: and understand the full picture of their health. Thanks for
- 7:12Speaker 1: this insightful dive into the mechanics of statins and Q10.
- 7:16Speaker 1: This has been a fascinating conversation, so let's dig into
- 7:20Speaker 1: the nitty-gritty here on the surface. The industry's narrative about
- 7:24Speaker 1: statins is straightforward, lower cholesterol, reduce heart attack risk. But, Thomas,
- 7:31Speaker 1: don't you find it odd how Terry is a disconnect
- 7:34Speaker 1: between this simple storyline and the complexity of the actual
- 7:37Speaker 1: mechanisms at play?
- 7:38Speaker 2: Absolutely, Rachel. To raise this assumption that lowering cholesterol is
- 7:42Speaker 2: the silver bullet for heart disease, but the reality is
- 7:46Speaker 2: far more complex. For instance, a 2014 study by the
- 7:50Speaker 2: Cochrane Collaboration on Statins showed no significant reduction in total mortality.
- 7:56Speaker 2: That's a big contradiction, isn't it?
- 7:58Speaker 1: Exactly. And when you factor in the body's natural production
- 8:02Speaker 1: of cholesterol, it throws a wrench into the works. It's
- 8:06Speaker 1: not just a problem of excess cholesterol. but also of balance. Q10,
- 8:11Speaker 1: for instance, is crucial for energy production, and statins interfere
- 8:16Speaker 1: with its production. So, we are essentially telling people to
- 8:19Speaker 1: take a drug that reduces their cholesterol, but also lowers
- 8:23Speaker 1: their Q10, which could have dire consequences.
- 8:27Speaker 2: It's like the industry is pushing a one-size-fits-all solution, which
- 8:32Speaker 2: is convenient for them, but not necessarily the best for
- 8:36Speaker 2: the patient. Plus, the AHA and ACC guidelines barely mention
- 8:41Speaker 2: Cotent supplementation, even though it could mitigate side effects. This
- 8:46Speaker 2: is where the conflict of interest comes into play. You see,
- 8:49Speaker 2: some committee members have financial ties with statin manufacturers, and
- 8:53Speaker 2: that could influence their recommendations.
- 8:56Speaker 1: That's wild when you look at the raw numbers. Statins
- 8:59Speaker 1: are the most prescribed medications today, with 93 million people
- 9:04Speaker 1: in the U.S. taking them. Given that, It's surprising that
- 9:08Speaker 1: the guidelines aren't more comprehensive. But the dossier makes a
- 9:12Speaker 1: compelling argument that we should be focusing on diet and
- 9:15Speaker 1: lifestyle changes as root cause interventions.
- 9:19Speaker 2: Right. The dossier pushes for a shift towards evidence-based medicine,
- 9:23Speaker 2: which prioritizes comprehensive patient care. And it raises a critical question.
- 9:28Speaker 2: Why are we not equipping patients with the full picture?
- 9:32Speaker 2: Patients should be informed that there are natural, holistic approaches
- 9:35Speaker 2: to managing cholesterol that should be discussed alongside statin use.
- 9:40Speaker 1: Exactly. Which brings up an interesting contradiction. The industry is
- 9:44Speaker 1: all about convenience and sales volumes. But at what cost
- 9:47Speaker 1: we should be advocating for transparency and patient autonomy? And
- 9:51Speaker 1: the fact that 12 meta-analyses show benefits from CU10 supplementation
- 9:55Speaker 1: is something we can't ignore. It's high time doctors and
- 9:59Speaker 1: health organizations start taking a more holistic approach.
- 10:03Speaker 2: That's the key takeaway, Rachel. Informed consent and patient education
- 10:08Speaker 2: are crucial. We need to move away from the one-size-fits-all
- 10:12Speaker 2: model and towards personalized health strategies that consider individual needs
- 10:17Speaker 2: and risks. This way, we can empower people to make
- 10:20Speaker 2: better choices and improve their overall well-being.
- 10:24Speaker 1: Well said, Thomas. As we continue to explore this, we
- 10:28Speaker 1: are really pushing the boundaries of conventional wisdom and exposing
- 10:32Speaker 1: the complexities. This has been a fascinating conversation, and I
- 10:36Speaker 1: believe our listeners will find it incredibly insightful. Speaking of
- 10:40Speaker 1: key quotes, have you read that one from Dr. Peter
- 10:43Speaker 1: Lange's Thomas? When you take a statin, you are blocking
- 10:47Speaker 1: the production of cholesterol. But you are also at the
- 10:50Speaker 1: same time blocking the production of something your heart and
- 10:53Speaker 1: your muscles depend on. And that is called coenzyme Q10.
- 10:57Speaker 2: Exactly, Rachel. It's a critical point, and it brings up
- 11:01Speaker 2: a whole new layer of complexity. The body produces 75%
- 11:06Speaker 2: of its cholesterol for essential functions like cell membrane construction
- 11:10Speaker 2: and hormone synthesis, as mentioned in Module 3. This means
- 11:14Speaker 2: lowering cholesterol can have unintended consequences. Right.
- 11:18Speaker 1: This quote is a stark reminder that the simple narrative
- 11:21Speaker 1: of lowering cholesterol to reduce heart attack risk is too simplistic.
- 11:25Speaker 1: It overlooks the deeper root causes of high cholesterol, as
- 11:29Speaker 1: well as the potential negative impacts on mitochondrial function. which
- 11:32Speaker 1: can be crucial for muscle health and overall energy production.
- 11:36Speaker 2: And let's not forget the meta-analysis by Dr. Sarah Thompson,
- 11:40Speaker 2: showing that 12 human randomized controlled trials found significant benefits
- 11:44Speaker 2: from taking CoQ10 in preventing statin side effects. It's like
- 11:48Speaker 2: the body is trying to tell us something.
- 11:50Speaker 1: Absolutely. The future outlook should be moving towards root cause interventions,
- 11:56Speaker 1: not just symptom management. That's why I believe we are
- 11:59Speaker 1: seeing a shift in medical practices. Doctors are starting to
- 12:02Speaker 1: prioritize lifestyle changes and preventive care before resorting to medication.
- 12:07Speaker 2: Exactly. And this brings us to the unsolved questions. Rachel,
- 12:11Speaker 2: why do health organizations like the AHA and ACC maintain
- 12:15Speaker 2: an insufficient stance on CoQ10 despite the strong evidence? Could
- 12:19Speaker 2: it be due to financial influences or a preference for
- 12:22Speaker 2: the status quo?
- 12:23Speaker 1: It's a valid point, Thomas. Informed consent and patient education
- 12:28Speaker 1: are crucial here. We need to empower people to make
- 12:32Speaker 1: better choices by providing them with all the necessary information.
- 12:36Speaker 1: This way, they can take a more active role in
- 12:39Speaker 1: their own health.
- 12:40Speaker 2: Exactly. Wait, but how does that actually play out in practice?
- 12:44Speaker 2: Let's consider the case of John, a 55-year-old who has
- 12:49Speaker 2: been on statins for over a decade. His cholesterol levels
- 12:52Speaker 2: are under control, but he is experiencing muscle weakness and fatigue,
- 12:56Speaker 2: common side effects of CUC-10 depletion. How should his doctor
- 13:00Speaker 2: advise him?
- 13:01Speaker 1: That's a great example, Thomas. The doctor should take a
- 13:04Speaker 1: more holistic approach, considering the underlying causes and symptoms. Perhaps
- 13:10Speaker 1: a discussion about dietary changes, exercise, and possibly Coq10 supplementation
- 13:16Speaker 1: could be beneficial. After all, the goal should be to
- 13:20Speaker 1: help John live a healthier life, not just manage his cholesterol.
- 13:24Speaker 2: That's the key, Rachel. As we see more evidence supporting
- 13:27Speaker 2: the root cause approach, I believe we will start to
- 13:30Speaker 2: see a decrease in the overprescription of statins. More focus
- 13:33Speaker 2: on lifestyle changes and preventive care isn't just about reducing
- 13:37Speaker 2: risk factors. It's about improving overall well-being.
- 13:41Speaker 1: So, let's talk about where all of this leads us.
- 13:44Speaker 1: If we are to shift from statin reliance to something
- 13:47Speaker 1: more holistically beneficial for patients, what pathways should we consider?
- 13:52Speaker 2: There are several key strategies. Firstly, Let's push for better
- 13:57Speaker 2: research funding to delve deeper into the interactions between statins
- 14:00Speaker 2: and Coq10. We need to understand more about the full
- 14:04Speaker 2: metabolic profile of these drugs. Agreed.
- 14:07Speaker 1: This means more comprehensive studies that can help us develop
- 14:11Speaker 1: more targeted and effective treatments. But, on a practical level,
- 14:16Speaker 1: how can we start moving patients towards lifestyle changes?
- 14:20Speaker 2: Excellent question. For starters, we can integrate personalized nutrition plans
- 14:25Speaker 2: that address the root causes of high cholesterol, not just
- 14:29Speaker 2: symptom management. That might involve reducing sugar and processed carbs
- 14:34Speaker 2: in the diet while also encouraging nutrient-rich foods like those
- 14:38Speaker 2: high in Q10.
- 14:39Speaker 1: Exactly. And let's not forget the role of exercise. Regular
- 14:44Speaker 1: physical activity can boost cardiovascular health, reduce inflammation, and improve
- 14:50Speaker 1: overall metabolic function.
- 14:51Speaker 2: Absolutely. Speaking of which, how do we incentivize doctors to
- 14:56Speaker 2: prescribe these kinds of interventions instead of the quick fix
- 14:59Speaker 2: of a statin?
- 15:00Speaker 1: That's a good point. We might explore models where doctors
- 15:04Speaker 1: are paid based on patient outcomes, not just on prescriptions written.
- 15:09Speaker 1: This would encourage a more holistic approach to patient care.
- 15:12Speaker 2: True, and it could make a big difference. On the
- 15:15Speaker 2: flip side, what about patient education? How do we ensure
- 15:19Speaker 2: they understand the benefits and risks of both statins and
- 15:23Speaker 2: natural alternatives, like COTEN?
- 15:25Speaker 1: That's the million-dollar question. We need clear, actionable information that's accessible.
- 15:32Speaker 1: Perhaps we could collaborate with patient advocacy groups to create straightforward,
- 15:38Speaker 1: evidence-based guides that patients can use.
- 15:40Speaker 2: Definitely. And what about the role of health organizations like
- 15:44Speaker 2: the AHA and ACC? How do we nudge them to
- 15:48Speaker 2: update their guidelines to be more inclusive of Q10?
- 15:51Speaker 1: Great question. We could start by showing them the data,
- 15:55Speaker 1: highlighting the benefits of Q10 supplementation and how it complements
- 15:59Speaker 1: statin therapy. Perhaps even organized panel discussions or conferences where
- 16:05Speaker 1: experts can share these findings.
- 16:07Speaker 2: Absolutely. And let's push for more transparency from the pharmaceutical industry.
- 16:12Speaker 2: They should be actively involved in these discussions but not
- 16:15Speaker 2: driving the agenda.
- 16:16Speaker 1: Right. And that's the crucial nuance here. We need to
- 16:19Speaker 1: foster an environment where all stakeholders are working towards a
- 16:23Speaker 1: common goal, improving patient health, not just selling a drug.
- 16:28Speaker 2: Exactly, which brings up an interesting contradiction. These organizations have
- 16:33Speaker 2: a lot of influence over public policy, yet their recommendations
- 16:37Speaker 2: often seem skewed. We need to hold them accountable for
- 16:41Speaker 2: evidence-based practices.
- 16:43Speaker 1: That's a powerful point, Thomas. Moving forward, we can use
- 16:46Speaker 1: this dossier as a blueprint for change. It's all about
- 16:50Speaker 1: shifting the narrative from reactive care to proactive, patient-focused approaches.
- 16:55Speaker 1: That brings us to the end of today's episode. Thank
- 16:58Speaker 1: you so much for spending part of your day with me.
- 17:01Speaker 1: If you found this episode's tips helpful and want to
- 17:03Speaker 1: make sure you don't miss the next conversation, please take
- 17:06Speaker 1: a quick second to hit that subscribe or follow button
- 17:09Speaker 1: on whatever platform you are listening on. It's a completely
- 17:12Speaker 1: free way to support the show and helps more people
- 17:15Speaker 1: find us. This podcast is independently produced, so if you
- 17:19Speaker 1: are ever in a position where you would like to
- 17:20Speaker 1: help keep it running, we do accept small donations. You
- 17:25Speaker 1: can find a link right in the episode description below
- 17:27Speaker 1: to buy us a coffee or contribute what you can.
- 17:30Speaker 1: Every bit genuinely helps. Take care of yourself, stay balanced,
- 17:35Speaker 1: and we will talk again soon.